Completed PHASE3 INTERVENTIONAL 2-arm NCT00081731

Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

Sponsor: Baim Institute for Clinical Research

Conditions Atherosclerosis Cardiovascular Diseases Hypertension, Renovascular Renal Artery Obstruction

Interventions Atacand/HCT, Caduet GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)

Updated 7 times since 2017 Last updated: Sep 18, 2015 Started: Apr 30, 2004 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00081731, this PHASE3 trial focuses on Atherosclerosis and Cardiovascular Diseases and remains completed. Sponsored by Baim Institute for Clinical Research, it has been updated 7 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baim Institute for Clinical Research
Beth Israel Deaconess Medical Center

Data source: Baim Institute for Clinical Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toledo, United States